Literature DB >> 25862589

Design and Validation of an Augmented Hematopoietic Cell Transplantation-Comorbidity Index Comprising Pretransplant Ferritin, Albumin, and Platelet Count for Prediction of Outcomes after Allogeneic Transplantation.

Jennifer E Vaughn1, Barry E Storer2, Philippe Armand3, Roberto Raimondi4, Christopher Gibson3, Alessandro Rambaldi5, Fabio Ciceri6, Rosi Oneto7, Benedetto Bruno8, Paul J Martin1, Brenda M Sandmaier1, Rainer Storb1, Mohamed L Sorror9.   

Abstract

Pretransplant values of serum ferritin, albumin, and peripheral blood counts were previously suggested to provide prognostic information about hematopoietic cell transplantation (HCT) outcomes. Whether these "biomarkers" have prognostic value independent of each other and the HCT-comorbidity index (HCT-CI) is unknown. We analyzed data from 3917 allogeneic HCT recipients at multiple sites in the United States and Italy using multivariate models including each biomarker and the HCT-CI. Data from all sites were then randomly divided into a training set (n = 2352) to develop weights for the relevant biomarkers to be added to the HCT-CI scores and a validation set (n = 1407) to validate an augmented HCT-CI compared with the original index. Multivariate analysis with data from one site showed that ferritin, albumin, and platelets-not neutrophils or hemoglobin-were independently associated with increased nonrelapse mortality (NRM) and decreased overall survival. Findings were validated in data from the other sites. Subsequently, in a training set from all sites, ferritin >2500 mg/dL (hazard ratio [HR], 1.69); albumin 3 to 3.5 g/dL (HR, 1.61) and <3.0 g/dL (HR, 2.27); and platelets 50 to <100,000 (HR, 1.28), 20 to <50,000 (HR, 1.29), and <20,000 (HR, 1.55) were statistically significantly associated with NRM. Weights were assigned to these laboratory values following the same equation used to design the original index. In the validation set, the addition of the biomarkers to the original index to develop an augmented HCT-CI resulted in a statistically significant increase in a higher c-statistic estimate for prediction of NRM (P = .0007). Ferritin, albumin, and platelet counts are important prognostic markers that further refine the discriminative power of the HCT-CI for transplant outcomes.
Copyright © 2015 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Albumin; Biomarkers; Ferritin; HCT-CI; HCT-comorbidity index; Hematopoietic cell transplantation; Platelet count survival

Mesh:

Substances:

Year:  2015        PMID: 25862589      PMCID: PMC4506728          DOI: 10.1016/j.bbmt.2015.04.002

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  37 in total

1.  Pretransplant serum ferritin level may be a predictive marker for outcomes in patients having undergone allogeneic hematopoietic stem cell transplantation.

Authors:  S Sivgin; S Baldane; L Kaynar; F Kurnaz; C Pala; A Ozturk; M Cetin; A Unal; B Eser
Journal:  Neoplasma       Date:  2012       Impact factor: 2.575

2.  Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index: a prospective, multicenter GITMO study.

Authors:  Roberto Raimondi; Alberto Tosetto; Rosi Oneto; Riccardo Cavazzina; Francesco Rodeghiero; Andrea Bacigalupo; Renato Fanin; Alessandro Rambaldi; Alberto Bosi
Journal:  Blood       Date:  2012-06-27       Impact factor: 22.113

3.  Does iron overload really matter in stem cell transplantation?

Authors:  Philippe Armand; Marie-Michele Sainvil; Haesook T Kim; Joanna Rhodes; Corey Cutler; Vincent T Ho; John Koreth; Edwin P Alyea; Ellis J Neufeld; Raymond Y Kwong; Robert J Soiffer; Joseph H Antin
Journal:  Am J Hematol       Date:  2012-04-04       Impact factor: 10.047

4.  Pre-transplantation iron chelation in patients with MDS or acute leukemia and iron overload undergoing myeloablative allo-SCT.

Authors:  P Armand; M-M Sainvil; H T Kim; J Rhodes; C Cutler; V T Ho; J Koreth; E P Alyea; E J Neufeld; R Y Kwong; R J Soiffer; J H Antin
Journal:  Bone Marrow Transplant       Date:  2012-05-21       Impact factor: 5.483

5.  Decreased serum albumin as a biomarker for severe acute graft-versus-host disease after reduced-intensity allogeneic hematopoietic cell transplantation.

Authors:  Andrew R Rezvani; Barry E Storer; Rainer F Storb; Marco Mielcarek; David G Maloney; Brenda M Sandmaier; Paul J Martin; George B McDonald
Journal:  Biol Blood Marrow Transplant       Date:  2011-07-30       Impact factor: 5.742

6.  MRI-based liver iron content predicts for nonrelapse mortality in MDS and AML patients undergoing allogeneic stem cell transplantation.

Authors:  Martin Wermke; Anne Schmidt; Jan Moritz Middeke; Katja Sockel; Malte von Bonin; Claudia Schönefeldt; Sabine Mair; Verena Plodeck; Michael Laniado; Günter Weiss; Johannes Schetelig; Gerhard Ehninger; Igor Theurl; Martin Bornhäuser; Uwe Platzbecker
Journal:  Clin Cancer Res       Date:  2012-09-18       Impact factor: 12.531

7.  Iron overload in patients with acute leukemia or MDS undergoing myeloablative stem cell transplantation.

Authors:  Philippe Armand; Haesook T Kim; Joanna Rhodes; Marie-Michele Sainvil; Corey Cutler; Vincent T Ho; John Koreth; Edwin P Alyea; Doreen Hearsey; Ellis J Neufeld; Mark D Fleming; Hanno Steen; Damon Anderson; Raymond Y Kwong; Robert J Soiffer; Joseph H Antin
Journal:  Biol Blood Marrow Transplant       Date:  2010-09-18       Impact factor: 5.742

8.  Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS.

Authors:  H Joachim Deeg; Bart L Scott; Min Fang; Howard M Shulman; Boglarka Gyurkocza; David Myerson; John M Pagel; Uwe Platzbecker; Aravind Ramakrishnan; Jerald P Radich; Brenda M Sandmaier; Mohamed Sorror; Derek L Stirewalt; Wendy A Wilson; Rainer Storb; Frederick R Appelbaum; Ted Gooley
Journal:  Blood       Date:  2012-07-05       Impact factor: 22.113

9.  Association of iron overload with allogeneic hematopoietic cell transplantation outcomes: a prospective cohort study using R2-MRI-measured liver iron content.

Authors:  Bryan J Trottier; Linda J Burns; Todd E DeFor; Sarah Cooley; Navneet S Majhail
Journal:  Blood       Date:  2013-06-18       Impact factor: 22.113

10.  The impact of pretransplant hypoalbuminemia on survival in patients with leukemia who underwent allogeneic hematopoietic stem cell transplantation (alloHSCT): a nutritional problem?

Authors:  S Sivgin; S Baldane; T Ozenmis; M Keklik; L Kaynar; F Kurnaz; H Sivgin; G Zararsız; M Cetin; A Unal; B Eser
Journal:  Transplant Proc       Date:  2013-11       Impact factor: 1.066

View more
  20 in total

1.  Prognostic Performance of the Augmented Hematopoietic Cell Transplantation-Specific Comorbidity/Age Index in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation from Alternative Graft Sources.

Authors:  Mahmoud Elsawy; Barry E Storer; Filippo Milano; Brenda M Sandmaier; Colleen Delaney; Rachel B Salit; Ahmed H Rashad; Ann E Woolfrey; Frederick R Appelbaum; Rainer Storb; Mohamed L Sorror
Journal:  Biol Blood Marrow Transplant       Date:  2018-11-28       Impact factor: 5.742

Review 2.  Up-to-date tools for risk assessment before allogeneic hematopoietic cell transplantation.

Authors:  M Elsawy; M L Sorror
Journal:  Bone Marrow Transplant       Date:  2016-06-06       Impact factor: 5.483

3.  Pre-transplant ferritin, albumin and haemoglobin are predictive of survival outcome independent of disease risk index following allogeneic stem cell transplantation.

Authors:  L Chee; M Tacey; B Lim; A Lim; J Szer; D Ritchie
Journal:  Bone Marrow Transplant       Date:  2017-05-15       Impact factor: 5.483

4.  The prognostic value of serum C-reactive protein, ferritin, and albumin prior to allogeneic transplantation for acute myeloid leukemia and myelodysplastic syndromes.

Authors:  Andrew S Artz; Brent Logan; Xiaochun Zhu; Gorgun Akpek; Rodrigo Martino Bufarull; Vikas Gupta; Hillard M Lazarus; Mark Litzow; Alison Loren; Navneet S Majhail; Richard T Maziarz; Philip McCarthy; Uday Popat; Wael Saber; Stephen Spellman; Olle Ringden; Amittha Wickrema; Marcelo C Pasquini; Kenneth R Cooke
Journal:  Haematologica       Date:  2016-08-04       Impact factor: 9.941

5.  The Hematopoietic Cell Transplant Comorbidity Index predicts survival after allogeneic transplant for nonmalignant diseases.

Authors:  Monica S Thakar; Larisa Broglie; Brent Logan; Andrew Artz; Nancy Bunin; Lauri M Burroughs; Caitrin Fretham; David A Jacobsohn; Alison W Loren; Joanne Kurtzberg; Caridad A Martinez; Shin Mineishi; Adam S Nelson; Ann Woolfrey; Marcelo C Pasquini; Mohamed L Sorror
Journal:  Blood       Date:  2018-12-13       Impact factor: 22.113

Review 6.  Aging: Treating the Older Patient.

Authors:  Ashley Rosko; Andrew Artz
Journal:  Biol Blood Marrow Transplant       Date:  2016-11-15       Impact factor: 5.742

7.  Allogeneic Hematopoietic Cell Transplantation Using Treosulfan-Based Conditioning for Treatment of Marrow Failure Disorders.

Authors:  Lauri M Burroughs; Akiko Shimamura; Julie-An Talano; Jennifer A Domm; Kelsey K Baker; Colleen Delaney; Haydar Frangoul; David A Margolis; K Scott Baker; Eneida R Nemecek; Amy E Geddis; Brenda M Sandmaier; H Joachim Deeg; Rainer Storb; Ann E Woolfrey
Journal:  Biol Blood Marrow Transplant       Date:  2017-06-07       Impact factor: 5.742

8.  Low serum albumin levels prior to pediatric allogeneic HCT are associated with increased need for critical care interventions and increased 6-month mortality.

Authors:  Alicia M Teagarden; Jodi L Skiles; Andrew L Beardsley; Michael J Hobson; Elizabeth A S Moser; Jamie L Renbarger; Courtney M Rowan
Journal:  Pediatr Transplant       Date:  2017-07-02

9.  HLA-Haploidentical Hematopoietic Cell Transplantation for Treatment of Nonmalignant Diseases Using Nonmyeloablative Conditioning and Post-Transplant Cyclophosphamide.

Authors:  Kanwaldeep K Mallhi; Meera A Srikanthan; Kelsey K Baker; Haydar A Frangoul; Troy R Torgerson; Aleksandra Petrovic; Amy E Geddis; Paul A Carpenter; K Scott Baker; Brenda M Sandmaier; Monica S Thakar; Suzanne Skoda-Smith; Hans-Peter Kiem; Rainer Storb; Ann E Woolfrey; Lauri M Burroughs
Journal:  Biol Blood Marrow Transplant       Date:  2020-03-28       Impact factor: 5.742

10.  Impact of Pretransplantation Renal Dysfunction on Outcomes after Allogeneic Hematopoietic Cell Transplantation.

Authors:  Nosha Farhadfar; Ajoy Dias; Tao Wang; Caitrin Fretham; Saurabh Chhabra; Hemant S Murthy; Larisa Broglie; Anita D'Souza; Shahinaz M Gadalla; Robert Peter Gale; Shahrukh Hashmi; A Samer Al-Homsi; Gerhard C Hildebrandt; Peiman Hematti; David Rizzieri; Lynette Chee; Hillard M Lazarus; Christopher Bredeson; Edgar A Jaimes; Amer Beitinjaneh; Asad Bashey; Tim Prestidge; Maxwell M Krem; David I Marks; Stefanie Benoit; Jean A Yared; Taiga Nishihori; Richard F Olsson; Cesar O Freytes; Edward Stadtmauer; Bipin N Savani; Mohamed L Sorror; Siddhartha Ganguly; John R Wingard; Marcelo Pasquini
Journal:  Transplant Cell Ther       Date:  2021-02-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.